Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1979 1
1980 1
1981 5
1982 3
1984 1
1986 2
1987 1
1990 2
1991 3
1992 4
1993 1
1996 2
1998 4
1999 2
2000 3
2001 4
2003 7
2004 1
2005 2
2007 1
2008 4
2009 4
2010 5
2011 1
2012 9
2013 6
2014 5
2015 10
2016 11
2017 7
2018 9
2019 12
2020 16
2021 23
2022 19
2023 17
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

181 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial.
Kaasch AJ, López-Cortés LE, Rodríguez-Baño J, Cisneros JM, Dolores Navarro M, Fätkenheuer G, Jung N, Rieg S, Lepeule R, Coutte L, Bernard L, Lemaignen A, Kösters K, MacKenzie CR, Soriano A, Hagel S, Fantin B, Lafaurie M, Talarmin JP, Dinh A, Guimard T, Boutoille D, Welte T, Reuter S, Kluytmans J, Martin ML, Forestier E, Stocker H, Vitrat V, Tattevin P, Rommerskirchen A, Noret M, Adams A, Kern WV, Hellmich M, Seifert H; SABATO study group. Kaasch AJ, et al. Among authors: lafaurie m. Lancet Infect Dis. 2024 May;24(5):523-534. doi: 10.1016/S1473-3099(23)00756-9. Epub 2024 Jan 17. Lancet Infect Dis. 2024. PMID: 38244557 Clinical Trial.
Antimicrobial for 7 or 14 Days for Febrile Urinary Tract Infection in Men: A Multicenter Noninferiority Double-Blind, Placebo-Controlled, Randomized Clinical Trial.
Lafaurie M, Chevret S, Fontaine JP, Mongiat-Artus P, de Lastours V, Escaut L, Jaureguiberry S, Bernard L, Bruyere F, Gatey C, Abgrall S, Ferreyra M, Aumaitre H, Aparicio C, Garrait V, Meyssonnier V, Bourgarit-Durand A, Chabrol A, Piet E, Talarmin JP, Morrier M, Canoui E, Charlier C, Etienne M, Pacanowski J, Grall N, Desseaux K, Empana-Barat F, Madeleine I, Bercot B, Molina JM, Lefort A; PROSTASHORT Study Group. Lafaurie M, et al. Clin Infect Dis. 2023 Jun 16;76(12):2154-2162. doi: 10.1093/cid/ciad070. Clin Infect Dis. 2023. PMID: 36785526 Clinical Trial.
Effectiveness of third-generation cephalosporins or piperacillin compared with cefepime or carbapenems for severe infections caused by wild-type AmpC β-lactamase-producing Enterobacterales: A multi-centre retrospective propensity-weighted study.
Maillard A, Delory T, Bernier J, Villa A, Chaibi K, Escaut L, Contejean A, Bercot B, Robert J, El Alaoui F, Tankovic J, Poupet H, Cuzon G, Lafaurie M, Surgers L, Joseph A, Paccoud O, Molina JM, Bleibtreu A; Treatment of AmpC-producing Enterobacterales Study Group. Maillard A, et al. Among authors: lafaurie m. Int J Antimicrob Agents. 2023 Jul;62(1):106809. doi: 10.1016/j.ijantimicag.2023.106809. Epub 2023 Apr 6. Int J Antimicrob Agents. 2023. PMID: 37028731
A highly virulent variant of HIV-1 circulating in the Netherlands.
Wymant C, Bezemer D, Blanquart F, Ferretti L, Gall A, Hall M, Golubchik T, Bakker M, Ong SH, Zhao L, Bonsall D, de Cesare M, MacIntyre-Cockett G, Abeler-Dörner L, Albert J, Bannert N, Fellay J, Grabowski MK, Gunsenheimer-Bartmeyer B, Günthard HF, Kivelä P, Kouyos RD, Laeyendecker O, Meyer L, Porter K, Ristola M, van Sighem A, Berkhout B, Kellam P, Cornelissen M, Reiss P, Fraser C; Netherlands ATHENA HIV Observational Cohort†; BEEHIVE Collaboration†. Wymant C, et al. Science. 2022 Feb 4;375(6580):540-545. doi: 10.1126/science.abk1688. Epub 2022 Feb 3. Science. 2022. PMID: 35113714 Free article.
Risk of Immune Thrombocytopenia After Influenza Vaccine.
Lafaurie M, Lapeyre-Mestre M, Sailler L, Sommet A, Moulis G. Lafaurie M, et al. JAMA Intern Med. 2022 Apr 1;182(4):444-445. doi: 10.1001/jamainternmed.2021.8523. JAMA Intern Med. 2022. PMID: 35188544 Free PMC article.
Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases.
Boumaza X, Lafaurie M, Treiner E, Walter O, Pugnet G, Martin-Blondel G, Biotti D, Ciron J, Constantin A, Tauber M, Puisset F, Moulis G, Alric L, Renaudineau Y, Chauveau D, Sailler L. Boumaza X, et al. Among authors: lafaurie m. Int Immunopharmacol. 2023 Jul;120:110342. doi: 10.1016/j.intimp.2023.110342. Epub 2023 Jun 3. Int Immunopharmacol. 2023. PMID: 37276827
Not all β-lactams are equal regarding neurotoxicity.
Chaïbi K, Chaussard M, Soussi S, Lafaurie M, Legrand M. Chaïbi K, et al. Among authors: lafaurie m. Crit Care. 2016 Oct 27;20(1):350. doi: 10.1186/s13054-016-1522-z. Crit Care. 2016. PMID: 27784324 Free PMC article. No abstract available.
181 results